Diffuse Scleroderma

Tocilizumab treatment in early interstitial lung disease, with progressive skin involvement related to systemic sclerosis, was able to stabilize forced vital capacity over 48 weeks, according to data published in Arthritis & Rheumatology.

SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.